Clinical Trials Resource Center

New Medical Therapies™

Affective Disorders

Patient Medical Areas

April 4, 2005

Saegis Pharmaceuticals reported positive results from a phase I trial investigating SGS518, a selective antagonist of the 5-HT6 serotonin receptor for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS). The drug is thought to enhance brain chemical transmission. Clinical results found the drug to be safe and well tolerated. The placebo-controlled, blinded study enrolled healthy subjects who were dosed in two cohorts: a single-dose, dose-ranging arm, followed by a multi-dose arm. The study’s primary objective was to evaluate the safety, tolerability and pharmacokinetics of SGS518. Saegis is developing SGS518 in partnership with Eli Lilly.

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.